Dendreon Annual Shareholders Meeting

Dendreon, the Seattle-based developer of an immune-boosting treatment for prostate cancer, is holding its annual shareholders meeting at its headquarters in Belltown. Shareholders are being asked to elect two new members to the company’s 12-member board of directors, and give the company (NASDAQ: DNDN) the ability to sell another 100 million shares of stock if it chooses.